Immunotherapy and Mesothelioma Prognosis Further, a July 2021 clinical trial tested atezolizumab (Tecentriq) plus bevacizumab (Avastin) in peritoneal mesothelioma patients. The 1-year survival rate in this study was 85%, and 61% of patients didn't see their cancer spread in this trial.